A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 1)
← catalyst calendarSponsored by Sanofi (industry) · SNY — their whole pipeline →. With Regeneron Pharmaceuticals.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
142actual
Sites
63
Countries
Argentina, Canada, Chile +14
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-11-28 | actual | When the study began enrolling |
| Primary completion | 2026-06-08 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-08-31 | estimated | The whole study's end, after follow-up |
| First posted | 2024-11-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Lichen Simplex Chronicus
Interventions
- Drug: Dupilumab — also filed as SAR231893, Dupixent
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFProportion of participants with improvement (reduction) in weekly average of daily WI-NRS by ≥4 from baseline to Week 24
measured Week 24
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed